Table 2.

The IC₅₀ Values of Carboplatin in the Primary Cell Cultures of Ovarian/Fallopian Tube Cancer Patients and Their Response to Chemotherapy

Patients	IC50 to carboplatin	Clinical response to chemotherapy	Patients	IC50 to carboplatin	Clinical response to chemotherapy
Patient 1	275 ± 7.071 μM	Nonresponsive	Patient 11	125 ± 4.630 μM	Responsive
Patient 2	500 ± 3.536 μM	Responsive	Patient 12	132 ± 4.950 μM	Responsive
Patient 3	295 ± 4.681 μM	No follow up data	Patient 13	250 ± 2.828 μM	No follow up data
Patient 4	320 ± 5.090 μM	Nonresponsive	Patient 14	500 ± 3.36 uM	During treatment
Patient 5	345 ± 7.012 μM	Expired before chemotherapy	Patient 15	>500 μM	Nonresponsive
Patient 6	480 ± 5.341 μM	Responsive	Patient 16	168 ± 4.243 μM	During treatment
Patient 7	180 ± 5.657 μM	No follow up data	Patient 17	340 ± 5.657 μM	During treatment
Patient 8	175 ± 8.55 μM	During BEP regimen treatment	Patient 18	132 ± 7.638 μM	Responsive
Patient 9	500 ± 0.013 μM	Responsive	Patient 19	250 ± 4.43 μM	During treatment
Patient 10	500 ± 6.633 μM	Responsive

The values are presented in the mean ± SD of three independent experiments. 50% inhibitory concentration (IC₅₀) was calculated from dose-response curves determined by the MTT assay. The correlation of IC₅₀ to carboplatin and clinical response was analyzed by the Spearman’s test and the result showed that there was no significant correlation (P=0.829).